KalVista Pharmaceuticals (NASDAQ: KALV), a pharmaceutical company which has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME), has announced the appointment of Paul Audhya, MD as its Chief Medical Officer. Dr. Audhya has over 20 years of clinical development and global medical affairs leadership experience across a range of therapeutic areas and disciplines, including rare disease.
Most recently, Dr. Audhya was Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals, Inc., where he established and provided oversight for all medical affairs functions including Health Economics and Outcomes Research and Global Patient Advocacy. Prior to that, he was Vice President, Global Strategy and Phase 4, Global Medical Affairs at Vertex Pharmaceuticals, Inc., where he led global launch and lifecycle management planning and implementation for the cystic fibrosis portfolio. Before Vertex, Dr. Audhya was Vice President, Medical Affairs at Hospira Inc. (acquired by Pfizer) where he introduced transformational strategies for biosimilars globally and led the successful launch of the first monoclonal biosimilar in the EU. In the years prior to Hospira, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Reata Pharmaceuticals, Abbott Laboratories, Amgen, Bristol Myers Squibb and Janssen.
Dr. Audhya received a BA and MD from New York University, an MBA from Pepperdine University, and completed his residency in Internal Medicine at the University of Medicine and Dentistry of New Jersey.